Zhou Li, Zhang Zhe, Huang Zhao, Nice Edouard, Zou Bingwen, Huang Canhua
State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, and West China School of Basic Sciences & Forensic Medicine, Sichuan University, and Collaborative Innovation Center for Biotherapy, Chengdu, 610041, P.R. China.
Department of Biochemistry and Molecular Biology, Monash University, Clayton, Victoria, 3800, Australia.
Mol Biomed. 2020 Aug 31;1(1):4. doi: 10.1186/s43556-020-00004-1.
Cancer is one of the most common disease worldwide, with complex changes and certain traits which have been described as "The Hallmarks of Cancer." Despite increasing studies on in-depth investigation of these hallmarks, the molecular mechanisms associated with tumorigenesis have still not yet been fully defined. Recently, accumulating evidence supports the observation that microRNAs and long noncoding RNAs (lncRNAs), two main classes of noncoding RNAs (ncRNAs), regulate most cancer hallmarks through their binding with DNA, RNA or proteins, or encoding small peptides. Reactive oxygen species (ROS), the byproducts generated during metabolic processes, are known to regulate every step of tumorigenesis by acting as second messengers in cancer cells. The disturbance in ROS homeostasis leads to a specific pathological state termed "oxidative stress", which plays essential roles in regulation of cancer progression. In addition, the interplay between oxidative stress and ncRNAs is found to regulate the expression of multiple genes and the activation of several signaling pathways involved in cancer hallmarks, revealing a potential mechanistic relationship involving ncRNAs, oxidative stress and cancer. In this review, we provide evidence that shows the essential role of ncRNAs and the interplay between oxidative stress and ncRNAs in regulating cancer hallmarks, which may expand our understanding of ncRNAs in the cancer development from the new perspective.
Antioxid Redox Signal. 2020-12-10
Antioxid Redox Signal. 2017-8-11
Adv Exp Med Biol. 2016
Methods Mol Biol. 2018
Front Cell Dev Biol. 2021-11-3
Cancer Cell Int. 2021-12-7
Cancer Lett. 2018-4-10
Mol Cell Biochem. 2025-3
Fundam Res. 2023-7-2
Pharmaceuticals (Basel). 2023-10-1
Mol Cancer. 2023-6-30
J Exp Clin Cancer Res. 2021-4-10
Sichuan Da Xue Xue Bao Yi Xue Ban. 2021-1
Cell Prolif. 2020-4-6
Eur Rev Med Pharmacol Sci. 2020-3
Biomed Pharmacother. 2020-2-25
J Exp Clin Cancer Res. 2020-2-3